Chien-Chih Chou

Chien-Chih Chou

Auto-generated profile, based on publicly available information

Chien-Chih Chou

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2024 in Ophthalmology
Verified
Journal Article
Closed access
CCChien-Chih Chou
Chien-Chih Chou
SPSsu-Yu Pan
Ssu-Yu Pan
YSYi-Jing Sheen
Yi-Jing Sheen
JLJun-Fu Lin
Jun-Fu Lin
CLChing-Heng Lin
Ching-Heng Lin
CWChien-Hsiang Weng
Chien-Hsiang Weng

8 March 2015 in BMC Surgery
Verified
Journal Article
Open access
PDF file
CCChien-Chih Chou
Chien-Chih Chou
HCHsin-Han Chen
Hsin-Han Chen
YTYi-Yu Tsai
Yi-Yu Tsai
YLYou-Ling Li
You-Ling Li
HLHui-Ju Lin
Hui-Ju Lin
We reported a case of sudden monocular vision loss after calcium hydroxyapatite (CaHA) injection into the nasal tip and dorsum with detailed retina images. A healthy, 35-year-old woman received CaHA filler injection for nose augmentation. Ten minutes after the procedure, she developed nausea, vomiting, headache, ptosis, and left periorbital pain. After 30 minutes, she complained of progressively blurring vision in the left eye. The best-corrected visual acuity (BCVA) in her left eye was 30 cm ahead of hand motion. Left exotropia was noted in primary gaze. Limitations in adduction, supraduction, and infraduction of the left eye were also observed. Slit lamp examination of the left eye revealed a pink conjunctiva, a clear cornea, a mild anterior chamber reaction, a sluggish papillary light reflex, and a semi-dilated pupil. A positive relative afferent pupillary defect was observed in the left eye. Fundus examination revealed optic disc edema and some linear whitish opacity over the superior and temporal sites in the left eye, suggesting multiple CaHA emboli in the choroid vessels. Although the majority of adverse reactions are mild and transient, surgeons should be alert about extremely rare serious adverse events such as visual loss.

7 February 2025 in Ophthalmology Science
Verified
Journal Article
Open access
SPSsu-Yu Pan
Ssu-Yu Pan
CWChien-Hsiang Weng
Chien-Hsiang Weng
STShang-Feng Tsai
Shang-Feng Tsai
YSYi-Jing Sheen
Yi-Jing Sheen
HLHui-Ju Lin
Hui-Ju Lin
CCChien-Chih Chou
Chien-Chih Chou
To evaluate whether glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with reduced retinal vein occlusion (RVO) risk compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM). A multinational, retrospective cohort study. Adults with T2DM newly prescribed GLP-1RAs or DPP-4 inhibitors between 2006 and 2023 were included in our analysis. This study leveraged data from populations across 21 countries. Propensity score matching at a 1:1 ratio balanced age, sex, race, glycated hemoglobin (HbA1c), body mass index (BMI), estimated glomerular filtration rate, medications, and comorbidities between GLP-1RA and DPP4 inhibitor users. We observed the occurrence of incident RVO and branch RVO (BRVO) in the overall population and in subpopulations stratified by age, sex, race, GLP-1RA type, baseline HbA1c, BMI, and diabetes duration. Among 79 486 matched participants, GLP-1RA use is associated with a lower risk of RVO (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.54–0.98) and BRVO (HR, 0.62; 95% CI, 0.41–0.95) over 5 years compared with DPP-4 inhibitor use. This association is consistent among patients aged ≥50 years, Blacks, those prescribed human-analog GLP-1RAs, and those with baseline HbA1c ≥8%, BMI ≥30 kg/m2, and diabetes duration ≥3 years. Glucagon-like peptide-1 receptor agonist use was linked to reduced RVO and BRVO risks in patients with T2DM when compared with DPP-4 inhibitor use, particularly in high-risk populations, suggesting potential benefits of GLP-1RAs over DPP-4 inhibitors in managing ocular complications in T2DM. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

30 August 2024 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
SPSsu-Yu Pan
Ssu-Yu Pan
YCYun-Yu Chen
Yun-Yu Chen
MHMin-Yen Hsu
Min-Yen Hsu
YSYi-Jing Sheen
Yi-Jing Sheen
CWChien-Hsiang Weng
Chien-Hsiang Weng
CCChien-Chih Chou
Chien-Chih Chou

5 March 2021 in Life
Verified
Journal Article
Open access
PDF file
LYLi yu-hsuan
Li yu-hsuan
WSWayne Huey-Herng Sheu
Wayne Huey-Herng Sheu
CCChien-Chih Chou
Chien-Chih Chou
CLChun-Hsien Lin
Chun-Hsien Lin
YCYUANSHAO CHENG
YUANSHAO CHENG
ILI-Te Lee
I-Te Lee
Deep learning-based software is developed to assist physicians in terms of diagnosis; however, its clinical application is still under investigation. We integrated deep-learning-based software for diabetic retinopathy (DR) grading into the clinical workflow of an endocrinology department where endocrinologists grade for retinal images and evaluated the influence of its implementation. A total of 1432 images from 716 patients and 1400 images from 700 patients were collected before and after implementation, respectively. Using the grading by ophthalmologists as the reference standard, the sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) to detect referable DR (RDR) were 0.91 (0.87–0.96), 0.90 (0.87–0.92), and 0.90 (0.87–0.93) at the image level; and 0.91 (0.81–0.97), 0.84 (0.80–0.87), and 0.87 (0.83–0.91) at the patient level. The monthly RDR rate dropped from 55.1% to 43.0% after implementation. The monthly percentage of finishing grading within the allotted time increased from 66.8% to 77.6%. There was a wide range of agreement values between the software and endocrinologists after implementation (kappa values of 0.17–0.65). In conclusion, we observed the clinical influence of deep-learning-based software on graders without the retinal subspecialty. However, the validation using images from local datasets is recommended before clinical implementation.

24 May 2024 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
Min-Yen HsuMin-Yen Hsu
Min-Yen Hsu
KLKai-Shin Luo
Kai-Shin Luo
CCChien-Chih Chou
Chien-Chih Chou
YLYu-Hsiang Lin
Yu-Hsiang Lin
YHYU-CHIEN HUNG
YU-CHIEN HUNG
KCKuang-Hsi Chang
Kuang-Hsi Chang
Aims: Evidence showed that SGLT2 inhibitors have greater protective effects against retinal diseases compared to other hypoglycemic agents. Thus, we explore the association between SGLT2 inhibitor usage and macular degeneration (MD) in Taiwanese patients with diabetes. Methods: The National Health Insurance (NHI) program's claim data are released as the National Health Insurance Research Database (NHIRD). This database covers more than 99% of the residents in Taiwan. We included data on patients who were newly diagnosed with type 2 diabetes mellitus (ICD-9-CM: 250, exclude 250.1x; ICD-10-CM: E11), with an age at diagnosis of over 20 years as our study population. Patients who received (sodium-glucose cotransporter 2 inhibitor) SGLT2i (ATC code: A10BK) over 90 days in 2016–2019 were defined as the SGLT2i cohort. Conversely, patients who did never received SGLT2i were defined as the non-SGLT2i cohort. The exclusion criteria were having MD before the index date, receiving SGLT2i within 1–89 days, and missing data on sex, age, or days of SGLT2i usage. Two cohorts were matched by 1:1 propensity score matching, which was based on age, sex, payroll bracket grade, urbanization, comorbidities, and medications. Results: Compared to non-SGLT2i cohort, patients who received SGLT2i had a significantly lower risk of MD (adjusted hazard ratio = 0.70, 95%CI = 0.66–0.75). Conclusions: We found that SGLT2is has a strong protective effect against MD in patients with diabetes. SGLT2is may have benefits beyond glycemic control in patients with DR. However, additional clinical and experimental studies are required.